bluebird bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Somerville, mass.--(business wire)--bluebird bio, inc. (nasdaq: blue) today announced the outcome of the u.s. food and drug administration's (fda) cellular, tissue, and gene therapies advisory committee (ctgtac) discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell (rbc) transfusions. on the question “do the benefits of beti-cel outweigh the risks for the treatment of subjects with transfusion-dependent beta-thalas

Somerville, mass.--(business wire)--bluebird bio, inc. (nasdaq: blue) today announced the outcome of the u.s. food and drug administration's (fda) cellular, tissue, and gene therapies advisory committee (ctgtac) discussion of elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy (cald) in patients less than 18 years of age who do not have an available and willing human leukocyte antigen (hla)-matched sibling hematopoietic stem cell (hsc) donor. on the

Somerville, mass.--(business wire)--bluebird bio, inc. (nasdaq: blue) (“bluebird bio” or the “company”) today announced that nasdaq has halted trading of the company's common stock on thursday, june 9 and friday, june 10, 2022. the u.s. food and drug administration's (fda) cellular, tissue, and gene therapies advisory committee (ctgtac) is meeting to discuss the biologics licensing applications (blas) for betibeglogene autotemcel (beti-cel) and elivaldogene autotemcel (eli-cel). beti-cel is und

Somerville, mass.--(business wire)--bluebird bio, inc. (nasdaq: blue) (“bluebird bio” or the “company”) today announced that the u.s. food and drug administration (fda) posted briefing documents for the fda cellular, tissue and gene therapies advisory committee meeting to review elivaldogene autotemcel (eli-cel) for early active cerebral adrenoleukodystrophy (cald) in patients without a matched sibling donor and betibeglogene autotemcel (beti-cel) for the treatment of people with Β-thalassemia

Cambridge, mass.--(business wire)--following a review of its strategic priorities, bluebird bio, inc. (nasdaq: blue) today announced that the company is initiating a comprehensive restructuring intended to deliver up to $160 million in cost savings over the next two years. bluebird intends to sharpen its focus on near-term catalysts, including anticipated fda approvals for its gene therapies for beta-thalassemia and cerebral adrenoleukodystrophy in 2022, and the potential submission of a biolog

Bristol Myers Squibb and Bluebird Bio have drugs in their pipelines that could soon earn FDA approval.

The company may be about to turn things around.

bluebird bio has had its fair share of problems over the years, but remains a pioneering gene therapy company. Last week, an FDA Advisory Committee voted unanimously in favour of approving 2 of bluebird's drugs - for Beta thalassemia and cerebral adrenoleukodystrophy.

Although terrible economic data has imposed a bloodbath in the market, certain oversold stocks are ripe for a potential comeback. The post 7 Oversold Stocks on the Verge of Blasting Off appeared first on InvestorPlace.

Here's what you need to know about trading penny stocks on June 21st The post What to Know About Buying Penny Stocks on June 21st  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Things are definitely looking up, but a few thorny issues are still in play.

Management's comments at a virtual conference went over quite well.

There was some positive news for the sector last week, after gene editing player Bluebird Bio received the unanimous backing of the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies advisory committees for two separate therapies targeted at cerebral adrenoleukodystrophy and.

It skyrocketed yesterday, and not much has changed.

Check these three penny stocks out right now The post Penny Stocks to Buy Right Now? 3 to Watch in Mid-June 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.